885022-11-7

Basic information

• Product Name: 2-[6-(2'-methylsulfanyl-biphenyl-4-yl)-7-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-pyrazolo[3,4-c]pyridin-1-yl]-benzenesulfonamide
• CAS NO: 885022-11-7
• Molecular Weight: 558.605
• Mol File: 885022-11-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-[6-(2'-methylsulfanyl-biphenyl-4-yl)-7-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-pyrazolo[3,4-c]pyridin-1-yl]-benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[6-(2'-methylsulfanyl-biphenyl-4-yl)-7-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-pyrazolo[3,4-c]pyridin-1-yl]-benzenesulfonamide(885022-11-7)
• EPA Substance Registry System: 2-[6-(2'-methylsulfanyl-biphenyl-4-yl)-7-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-pyrazolo[3,4-c]pyridin-1-yl]-benzenesulfonamide(885022-11-7)

Safety Data

• Hazardous Substances Data: 885022-11-7(Hazardous Substances Data)

Upstream product

• 540-37-4 p-aminoiodobenzene 
• 3306-62-5 2-AMINOBENZENESULFONAMIDE 
• 4509-90-4 5-bromovaleroyl chloride 
• 473927-69-4 1-(4-iodo-phenyl)-3-morpholin-4-yl-5,6-dihydro-1H-pyridin-2-one 
• 545445-10-1 3,3-dichloro-1-(4-iodophenyl)-piperidin-2-one 
• 385425-15-0 1-(2-oxopiperidin-1-yl)-4-iodobenzene 
• 885022-13-9 2-[6-(4-iodo-phenyl)-7-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-pyrazolo[3,4-c]pyridin-1-yl]-benzenesulfonamide 
• 168618-42-6 (2-methylsulfanylphenyl)boronic acid 
• 90824-33-2 2-hydrazino-benzenesulfonamide 
• 536759-87-2 1-(4-iodophenyl)-3-(4-morpholinyl)-4-(trifluoroacetyl)-5,6-dihydro-2(1H)-pyridinone 
• 385425-14-9 1-(4-iodophenyl)-4-(2,2,2-trifluoroacetyl)-piperidine-2,3-dione 

Relevant articles and documents

Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties

The bicyclic dihydropyrazolopyridinone scaffold allowed for incorporation of multiple P1 moieties with subnanomolar binding affinities for blood coagulation factor Xa. The compound 3-[6-(2′-dimethylaminomethyl-biphenyl-4-yl)-7-oxo-3-trifluoro-methyl-4,5,6,7-tetrahydro-pyrazolo[3,4-c]pyridine-l-yl]-benzamide 6d shows good fXa potency, selectivity, in vivo efficacy and oral bioavailability. Compound 6d was selected for further pre-clinical evaluations.